Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2018

View Archived Issues

Novartis to acquire AveXis

Promethera Biosciences raises EUR 9.3 million and acquires Baliopharm

FDA requires extended time to review additional information regarding NDA for elagolix

Mylan acquiring global marketing rights to GA Depot

Schizophrenia mouse model reveals GPR139 as key for brain habenula functioning

Prescient Therapeutics presents successful phase Ib data for PTX-200 in breast cancer

Wave Life Sciences, Deep Genomics enter oligonucleotide drug collaboration

CIS-43 antibody targets new region of circumsporozoite protein to prevent malaria infection

Initiation of phase II BELIEVE 1 study of ZYN-002 in developmental and epileptic encephalopathies

Loxo Oncology and Illumina to develop pan-cancer companion diagnostics

Novel indoleamine 2,3-dioxygenase 1 inhibitors identified at Ensemble Therapeutics

Novartis patents agents for tendon and/or ligament injuries

Data monitoring committee recommends stopping phase III ATLAS study of Inlyta due to futility

New TRPV4 antagonists discovered at GlaxoSmithKline

Merck & Co. presents novel PCSK9 inhibitors

University of Ljubljana describes novel monoamine oxidase type B inhibitors

Alexion Pharmaceuticals makes recommended public cash offer to acquire Wilson Therapeutics

Chromosome locus 16p11.2 duplication tied to higher schizophrenia risk

First patient dosed in global phase II study of tislelizumab in previously treated HCC

Afinitor Disperz receives FDA approval for the treatment of TSC-associated partial-onset seizures

Helix BioPharma receives regulatory approval to dose patients in phase II study of L-DOS47

5-HTT radiotracer [11C]DASB may predict remission after antidepressant treatment

Spectrum provides update on phase II data for poziotinib in EGFR Exon 20 mutant NSCLC

Phase III RESOLVE-IT trial reaches target recruitment for the interim analysis cohort

European Commission approves Kineret for the treatment of Still's disease

A variant in HSD17B13 gene protects from chronic liver disease development

FDA grants fast track to selinexor for the treatment of penta-refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...